
Cytek Biosciences, Inc.: updates and filings
Price
$6.32
November 19, 2026Market cap $812M
What Ploutos Investor adds for Cytek Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Nov 3, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 29, 2026Amended articles or bylawsForm8-K
- Aug 24, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Aug 4, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 15, 2026Officer or director changeForm8-K
- Jul 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 25, 2026Officer or director changeForm8-K
- Jun 16, 2026Shareholder voteForm8-K
- Jun 2, 2026Officer or director changeForm8-K
- Jun 1, 2026Conflict minerals reportFormSD
- May 18, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 9, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 27, 2026Shares registered for employeesFormS-8
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Nov 3, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 29, 2026 | 8-K | Amended articles or bylaws | Document |
| Aug 24, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Aug 4, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 15, 2026 | 8-K | Officer or director change | Document |
| Jul 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 25, 2026 | 8-K | Officer or director change | Document |
| Jun 16, 2026 | 8-K | Shareholder vote | Document |
| Jun 2, 2026 | 8-K | Officer or director change | Document |
| Jun 1, 2026 | SD | Conflict minerals report | Document |
| May 18, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 9, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 27, 2026 | S-8 | Shares registered for employees | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 10, 2020.
The full analysis
What do Cytek Biosciences's filings show?
The filings are where every one of Cytek Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.